Today: 7 February 2026
Subscribe
Browse Category

Stock Market News 14 January 2026

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone shares fell 0.4% to 98.3 pence by 0932 GMT in London, after a 2.6% drop Tuesday, despite another buyback announcement. The company repurchased over 5.2 million shares on Jan. 13, adding to its treasury stock. Investors are awaiting Vodafone’s trading update on Feb. 5 for further direction. UBS maintained its “sell” rating but raised the target price to 82 pence.
14 January 2026
··
South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up

South Korea delays first STO exchange licences as Lucentblock-Nextrade fight heats up

South Korea’s Financial Services Commission delayed a decision on preliminary licenses for new over-the-counter marketplaces for tokenized securities at its Jan. 14 meeting. Lucentblock accused rival Nextrade of misusing confidential information, which Nextrade denied. The regulator was expected to pick up to two operators from three contenders. The delay leaves the selection unresolved and intensifies pressure on Lucentblock.
14 January 2026
··
Imperial Brands stock holds steady after fresh buyback disclosure; AGM and dividend dates loom

Imperial Brands stock holds steady after fresh buyback disclosure; AGM and dividend dates loom

Imperial Brands PLC repurchased 291,666 shares on Jan. 13 at an average price of 3,012.98 pence, canceling them to reduce shares outstanding to 793,362,213. Shares traded near 3,009 pence early Wednesday, little changed after the buyback news. The company’s annual meeting is set for Jan. 28, with a final dividend payment scheduled for March 31, pending approval.
14 January 2026
··
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
1 … 574 575 576 577 578 … 1,947

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop